This study aims to quantify methotrexate (MTX)-associated side effects in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients. In the ArthritisPower app and registry, a self-controlled case series study design with electronic patient-reported outcome measures (e-PROMs) was used.
This virtual, longitudinal study explores the different patient-reported outcomes (PROs) that patients with rheumatic and musculoskeletal diseases consider important for their disease management.
There is limited information available about the diagnostic experience of patients with psoriatic arthritis (PsA). 203 participants were interviewed and surveyed about their diagnostic journey with PsA. Participants reported delays in diagnosis and misdiagnoses and reported joint pain and stiffness as symptoms that led them to seek medical care. Participants with joint pain, swollen joints, and sausage-like fingers or toes were more likely to have a shorter time to diagnosis whereas fatigue, foot problems, stiffness, and back pain symptoms reported by participants led to longer diagnosis times.
In Clinical Rheumatology, Leverenz et al. report a study in which they investigated contraceptive methods used in young women with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) and correlated the efficacy of the contraceptive methods with the use of concomitant rheumatic medications. Of the 164 women included, women with RA and PsA reported similar utilization of highly effective contraception methods and effective methods, but different utilization of ineffective methods and no methods. These proportions remained similar across subgroups taking methotrexate, anti-TNF biologics, and novel medications. Women with PsA were more likely to report no methods of contraception.